Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 139

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 139
---
 price, placement agent fees and proceeds, before expenses, to us, assuming the purchase of all the securities we are
offering.

|                                  |     | Per Unit |     | Per Pre-Funded Unit |     | Total |
|:---------------------------------|:----|:---------|:----|:--------------------|:----|:------|
| Public offering price            |     | $        |     | $                   |     | $     |
| Placement agent fees             |     | $        |     | $                   |     | $     |
| Proceeds, before expenses, to us |     | $        |     | $                   |     | $     |

Placement Agent Warrants

The
placement agent intends to purchase Placement Agent Warrants to purchase up to a number of Depositary Shares equal to 5.0% of the units
sold in this offering at a an aggregate purchase price equal to the Nominal Value Amount. The Placement Agent Warrants will have an
exercise price equal to 100% of the offering price per Unit, subject to customary anti-dilution provisions consistent with FINRA Rule
5110(g)(8). The Placement Agent Warrants will be substantially similar to the Series L Warrants issued hereunder. As with the Series
L Warrants, the Placement Agent Warrants will expire five (5) years after the issuance date and do not provide for any registration rights.
The Placement Agent Warrants and the Depositary Shares (representing Ordinary Shares) are being registered on the registration statement
of which this prospectus is a part.

| 83 |

The Placement Agent Warrants and underlying
shares have been deemed compensation by FINRA. Pursuant to FINRA Rule 5110(e)(1), underwriting compensation consisting of securities must
not be sold, transferred, assigned, pledged or hypothecated nor may they be the subject of any hedging, short sale, derivative, put or
call transaction that would result in the economic disposition of the securities by any person for a period of 180 days following the
commencement of sales of this offering except to any placement agent and selected dealer participating in the offering and their officers
or partners, registered persons or affiliates or as otherwise permitted under FINRA Rule 5110(e)(2). Pursuant to FINRA Rule 5110(e)(2)(A)(iii),
the Placement Agent Warrants meet an exception to the lock-up restriction under Rule 5110(e)(1) because the Company meets the registration